News >

Combination Therapies Push Melanoma Field Forward

Danielle Bucco
Published: Monday, Dec 11, 2017

Michael A. Postow, MD

Michael A. Postow, MD
Combination therapy continues to propel the treatment landscape for patients with melanoma in a positive direction, according to Michael A. Postow, MD, who adds that an area of interest is the combination of BRAF and MEK inhibitors with PD-1 therapy as well as combinations of LAG-3 inhibition plus PD-1 agents.

on Melanoma, Postow, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the evolution of combination therapies for patients with melanoma.

OncLive®: Please provide an overview of your presentation on combination therapies for patients with melanoma.

Postow: There are many new combination therapies in patients with melanoma. For patients with BRAF-mutant melanoma, we are seeing combinations of BRAF and MEK inhibitors with immunotherapy drugs that are moving into randomized phase III studies. We will know if something improves when you add immunotherapy to BRAF and MEK inhibitors. Outside of that targeted therapy world for patients with BRAF-mutant melanoma, we are seeing new immuno-oncology combination agents.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x